Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of “Buy” by Brokerages

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have earned an average recommendation of “Buy” from the nineteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $71.8824.

A number of research firms recently issued reports on XENE. Needham & Company LLC lifted their target price on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a “buy” rating in a report on Monday, March 9th. Deutsche Bank Aktiengesellschaft upped their price target on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. increased their price target on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. HC Wainwright lifted their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Finally, Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th.

Insiders Place Their Bets

In related news, CEO Ian Mortimer sold 270,000 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at $361,980. This represents a 97.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Christopher John Kenney sold 2,771 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the sale, the insider owned 4,729 shares in the company, valued at approximately $284,260.19. This represents a 36.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 336,707 shares of company stock worth $19,622,565 in the last 90 days. Corporate insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XENE. Cinctive Capital Management LP increased its holdings in shares of Xenon Pharmaceuticals by 1.1% in the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after acquiring an additional 263 shares during the last quarter. Arizona State Retirement System lifted its stake in Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 334 shares during the last quarter. State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 350 shares in the last quarter. Quarry LP boosted its holdings in Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares in the last quarter. Finally, Altfest L J & Co. Inc. increased its stake in Xenon Pharmaceuticals by 6.5% in the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Stock Down 1.0%

Xenon Pharmaceuticals stock opened at $54.66 on Tuesday. The firm has a market cap of $4.55 billion, a PE ratio of -12.54 and a beta of 0.91. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $63.95. The company’s 50 day moving average is $43.97 and its two-hundred day moving average is $42.07.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the business posted ($0.84) EPS. On average, equities research analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.